InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Seven brokerages rate InflaRx as a "Moderate Buy" (five buys, one hold, one sell) with an average 1‑year price target of about $6.17.
• Market snapshot & results: Shares trade near $0.93 (1‑year range $0.71–$1.94) with a market cap of ~$67.2M; last quarter EPS was ($0.17) and analysts expect roughly −$1.04 EPS for the current fiscal year.
• Company focus: InflaRx is a clinical‑stage biopharma developing vilobelimab, an anti‑C5a monoclonal antibody for inflammatory diseases, with Phase II proof‑of‑concept data reported.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.1667.

Several brokerages have commented on IFRX. Raymond James Financial reiterated an "outperform" rating on shares of InflaRx in a research report on Wednesday, December 31st. Leerink Partners restated a "market perform" rating and issued a $2.00 price target (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of InflaRx in a research note on Monday, December 29th. Guggenheim dropped their price objective on InflaRx from $22.00 to $14.00 and set a "buy" rating for the company in a report on Friday, March 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of InflaRx in a research note on Tuesday, December 30th.

Institutional Trading of InflaRx

A number of hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its holdings in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after purchasing an additional 7,616 shares during the period. Woodline Partners LP acquired a new stake in InflaRx in the first quarter worth $766,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock worth $118,000 after purchasing an additional 91,927 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx in the 2nd quarter valued at $262,000. Finally, Squarepoint Ops LLC grew its holdings in shares of InflaRx by 29.1% in the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company's stock valued at $253,000 after buying an additional 42,489 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Trading Down 1.1%

Shares of NASDAQ IFRX opened at $0.93 on Friday. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The firm's 50-day moving average is $0.92 and its 200-day moving average is $1.13. The firm has a market capitalization of $67.23 million, a PE ratio of -1.22 and a beta of 1.48.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.17) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.17). The business had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. As a group, equities research analysts anticipate that InflaRx will post -1.04 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.